Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy

Alexandre Prat, Abdulla Al-Asmi, Pierre Duquette, Jack P. Antel

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalAnnals of Neurology
Volume46
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Multiple Sclerosis
Lymphocytes
Interferons
Relapsing-Remitting Multiple Sclerosis
Therapeutic Uses
Therapeutics
Fibronectins
Central Nervous System
Tissue Donors
Recurrence
Membranes
Glatiramer Acetate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lymphocyte migration and multiple sclerosis : Relation with disease course and therapy. / Prat, Alexandre; Al-Asmi, Abdulla; Duquette, Pierre; Antel, Jack P.

In: Annals of Neurology, Vol. 46, No. 2, 1999, p. 253-256.

Research output: Contribution to journalArticle

Prat, Alexandre ; Al-Asmi, Abdulla ; Duquette, Pierre ; Antel, Jack P. / Lymphocyte migration and multiple sclerosis : Relation with disease course and therapy. In: Annals of Neurology. 1999 ; Vol. 46, No. 2. pp. 253-256.
@article{f4ff89fd3ddf4332833edec0c8f1edfa,
title = "Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy",
abstract = "Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.",
author = "Alexandre Prat and Abdulla Al-Asmi and Pierre Duquette and Antel, {Jack P.}",
year = "1999",
doi = "10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C",
language = "English",
volume = "46",
pages = "253--256",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Lymphocyte migration and multiple sclerosis

T2 - Relation with disease course and therapy

AU - Prat, Alexandre

AU - Al-Asmi, Abdulla

AU - Duquette, Pierre

AU - Antel, Jack P.

PY - 1999

Y1 - 1999

N2 - Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.

AB - Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.

UR - http://www.scopus.com/inward/record.url?scp=0032838096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032838096&partnerID=8YFLogxK

U2 - 10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C

DO - 10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C

M3 - Article

C2 - 10443892

AN - SCOPUS:0032838096

VL - 46

SP - 253

EP - 256

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -